BAP1 Tumor Predisposition Syndrome — a recently characterized high-penetrance hereditary cancer syndrome where one gene variant predisposes to four different cancers simultaneously, many of which are extremely rare in the general population.
Whole genome sequencing identifies BAP1 pathogenic variants — established on the ACMG SF v3.2 list — in a syndrome where a single genetic result triggers surveillance for uveal melanoma, mesothelioma, cutaneous melanoma, and renal cell carcinoma.
BAP1 Tumor Predisposition Syndrome
BAP1 tumor predisposition syndrome (BAP1-TPDS) is an autosomal dominant hereditary cancer syndrome caused by germline pathogenic variants in BAP1 (BRCA1-associated protein 1) on chromosome 3p21.1. BAP1 is a deubiquitylase with roles in chromatin remodeling, DNA damage response, and cell cycle control. Germline BAP1 pathogenic variants were systematically characterized only from 2011 onward — the syndrome is relatively newly described, meaning many affected families accumulated multiple unusual cancers for generations without a hereditary explanation. BAP1-TPDS is now recognized as a high-penetrance multi-tumor predisposition syndrome.
The spectrum of tumors in BAP1-TPDS is distinctive — carriers face substantially elevated risks for: uveal melanoma (ocular melanoma, affecting the choroid/iris/ciliary body; >50 times the population risk), malignant pleural mesothelioma (a rare cancer strongly associated with asbestos exposure, now recognized as also occurring in BAP1 carriers with minimal or no asbestos history), cutaneous melanoma (multiple primary melanomas, often with distinctive melanocytic BAP1-mutated atypical intradermal tumors — 'BAPoma' lesions), and renal cell carcinoma (particularly clear cell and chromophobe subtypes). Each of these cancers is individually uncommon; their co-occurrence in a family is the epidemiological signal that identified BAP1-TPDS.
The clinical implications of a BAP1 molecular diagnosis are immediate and multi-specialty. Annual ophthalmic examination including fundoscopic evaluation (uveal melanoma surveillance), annual dermatological examination with dermatoscopy (cutaneous melanoma and BAPoma surveillance), renal imaging beginning in the third to fourth decade (RCC surveillance), annual chest imaging consideration (mesothelioma surveillance in exposed carriers), and cascade testing of all first-degree relatives are initiated at diagnosis. Critically, BAP1-associated mesothelioma is being recognized as a distinct clinical entity from asbestos-induced mesothelioma — BAP1 mesothelioma patients tend to be younger, have longer survival post-diagnosis, and may have different chemotherapy response profiles.
BAP1 was recognized as a hereditary cancer gene only after 2011 and is not included on many older hereditary cancer panels. Families with uveal melanoma, mesothelioma, or unusual cancer clustering may have BAP1-TPDS and never been appropriately tested.
BAP1 is missing from older hereditary cancer panels — families with unusual cancer histories were never tested
The systematic characterization of BAP1-TPDS began only in 2011. Many families with BAP1 pathogenic variants received hereditary cancer panels in the preceding decade that did not include BAP1. Individuals with family histories including uveal melanoma, mesothelioma, or unusual clustering of melanoma and renal cancer — the cardinal BAP1 tumor spectrum — may have received negative panel results from pre-2011 testing or from panels that never added BAP1 to their gene list. Whole genome sequencing evaluates the entire genome and identifies BAP1 pathogenic variants regardless of when the sequencing was performed, with no limitation of a pre-defined gene list.
A confirmed BAP1 result triggers four simultaneous cancer surveillance protocols
Unlike hereditary cancer syndromes where a single gene primarily predisposes to one cancer type, BAP1-TPDS requires coordinating surveillance across four distinct cancer types — uveal melanoma (ophthalmology), cutaneous melanoma (dermatology), renal cell carcinoma (urology/radiology), and mesothelioma (pulmonology/oncology). This multi-specialty coordination begins at first molecular diagnosis and continues annually for life. Each surveillance modality addresses a cancer that standard population screening does not include — no existing general cancer screening program covers uveal melanoma, and mesothelioma screening is not standard in undiagnosed BAP1 carriers. A molecular diagnosis is the prerequisite for activating this multi-organ surveillance network.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for BAP1 Tumor Predisposition Syndrome and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
